Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bryostatin analogues - Aphios Corporation

Next Previous
Drug Profile

Bryostatin analogues - Aphios Corporation

Alternative Names: APH-0703; APH-1104; Bryosomes; Bryostatin 1-containing phospholipid nanosomes (Bryosomes™) - Aphios; Nanoencapsulated APH 0703

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aphios Corporation
  • Developer Aphios Corporation; Louisiana State University; University Hospital Muenster
  • Class Antidementias; Antineoplastics; Lactones; Macrocyclic compounds; Nootropics
  • Mechanism of Action Amyloid beta-protein inhibitors; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Cognition disorders; Down syndrome; Reperfusion injury
  • Discontinued Oesophageal cancer

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (IV)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Cognition-disorders in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top